Cargando…

Expression of DNA repair and replication genes in non-small cell lung cancer (NSCLC): a role for thymidylate synthetase (TYMS)

BACKGROUND: BRCA1 (B), ERCC1 (E), RRM1 (R) and TYMS (T) mRNA expression has been extensively studied with respect to NSCLC patient outcome upon various chemotherapy agents. However, these markers have not been introduced into clinical practice yet. One of the reasons seems to be lack of a standard a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kotoula, Vassiliki, Krikelis, Dimitrios, Karavasilis, Vasilios, Koletsa, Triantafillia, Eleftheraki, Anastasia G, Televantou, Despina, Christodoulou, Christos, Dimoudis, Stefanos, Korantzis, Ippokratis, Pectasides, Dimitrios, Syrigos, Konstantinos N, Kosmidis, Paris A, Fountzilas, George
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3503623/ https://www.ncbi.nlm.nih.gov/pubmed/22866924 http://dx.doi.org/10.1186/1471-2407-12-342

Ejemplares similares

Volumetric and MGMT parameters in glioblastoma patients: Survival analysis
por: Iliadis, Georgios, et al.
Publicado: (2012)

Identification and Validation of a Multigene Predictor of Recurrence in Primary Laryngeal Cancer
por: Fountzilas, Elena, et al.
Publicado: (2013)

Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials
por: Fountzilas, George, et al.
Publicado: (2013)

Differential Response of Immunohistochemically Defined Breast Cancer Subtypes to Anthracycline-Based Adjuvant Chemotherapy with or without Paclitaxel
por: Fountzilas, George, et al.
Publicado: (2012)

alphaB-crystallin is a marker of aggressive breast cancer behavior but does not independently predict for patient outcome: a combined analysis of two randomized studies
por: Koletsa, Triantafyllia, et al.
Publicado: (2014)

Thymidylate synthase gene (TYMS) polymorphisms in sporadic and hereditary breast cancer
por: Junior, José da Silva Nogueira, et al.
Publicado: (2012)

Genetic mapping of pancreatic cancer by targeted next-generation sequencing in a cohort of patients managed with nab-paclitaxel-based chemotherapy or agents targeting the EGFR axis: a retrospective analysis of the Hellenic Cooperative Oncology Group (HeCOG)
por: Zarkavelis, George, et al.
Publicado: (2019)

MicroRNA-140-3p represses the proliferation, migration, invasion and angiogenesis of lung adenocarcinoma cells via targeting TYMS (thymidylate synthetase)
por: Wan, Shanzhi, et al.
Publicado: (2021)

Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer
por: Pectasides, Dimitrios, et al.
Publicado: (2015)

DARPP32, STAT5 and STAT3 mRNA Expression Ratios in Glioblastomas are Associated with Patient Outcome
por: Televantou, Despina, et al.
Publicado: (2012)

Immune Response Gene Expression in Colorectal Cancer Carries Distinct Prognostic Implications According to Tissue, Stage and Site: A Prospective Retrospective Translational Study in the Context of a Hellenic Cooperative Oncology Group Randomised Trial
por: Pentheroudakis, George, et al.
Publicado: (2015)

Genotyping data of routinely processed matched primary/metastatic tumor samples
por: Kotoula, Vassiliki, et al.
Publicado: (2020)

Prognostic significance of tumor genotypes and CD8+ infiltrates in stage I-III colorectal cancer
por: Fountzilas, Elena, et al.
Publicado: (2018)

FOXM1 modulates 5-fluorouracil sensitivity in cholangiocarcinoma through thymidylate synthase (TYMS): implications of FOXM1–TYMS axis uncoupling in 5-FU resistance
por: Intuyod, Kitti, et al.
Publicado: (2018)

Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer
por: Murray, Samuel, et al.
Publicado: (2012)

Sample parameters affecting the clinical relevance of RNA biomarkers in translational breast cancer research
por: Kotoula, Vassiliki, et al.
Publicado: (2012)

Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes
por: Pentheroudakis, George, et al.
Publicado: (2013)

Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy
por: Kostopoulos, Ioannis, et al.
Publicado: (2009)

HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy
por: Fountzilas, George, et al.
Publicado: (2012)

Overexpression of thymidylate synthase (TYMS) is associated with aggressive tumor features and early PSA recurrence in prostate cancer
por: Burdelski, Christoph, et al.
Publicado: (2015)

Pancytopenia and Severe Gastrointestinal Toxicities Associated with 5-Fluorouracil in a Patient with Thymidylate Synthase (TYMS) Polymorphism
por: Wang, Bo, et al.
Publicado: (2016)

Retraction Note to: FOXM1 modulates 5-fluorouracil sensitivity in cholangiocarcinoma through thymidylate synthase (TYMS): implications of FOXM1–TYMS axis uncoupling in 5-FU resistance
por: Intuyod, Kitti, et al.
Publicado: (2021)

Antitumor Activity of Fluoropyrimidines and Thymidylate Synthetase Inhibition
por: Kubota, Tetsuro, et al.
Publicado: (1991)

Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab
por: Fountzilas, George, et al.
Publicado: (2012)

Prognostic Significance of ESR1 Gene Amplification, mRNA/Protein Expression and Functional Profiles in High-Risk Early Breast Cancer: A Translational Study of the Hellenic Cooperative Oncology Group (HeCOG)
por: Pentheroudakis, George, et al.
Publicado: (2013)

MicroRNA-433 negatively regulates the expression of thymidylate synthase (TYMS) responsible for 5-fluorouracil sensitivity in HeLa cells
por: Gotanda, Keisuke, et al.
Publicado: (2013)

Delayed malignant melanoma recurrence simulating primary ovarian cancer: Case report
por: Boutis, Anastasios, et al.
Publicado: (2008)

Prognostic implications of mismatch repair deficiency in patients with nonmetastatic colorectal and endometrial cancer
por: Fountzilas, Elena, et al.
Publicado: (2019)

Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study
por: Papaxoinis, George, et al.
Publicado: (2015)

TP53 mutations and protein immunopositivity may predict for poor outcome but also for trastuzumab benefit in patients with early breast cancer treated in the adjuvant setting
por: Fountzilas, George, et al.
Publicado: (2016)

MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer
por: Gogas, Helen, et al.
Publicado: (2016)

Ixabepilone Administered Weekly or Every Three Weeks in HER2-Negative Metastatic Breast Cancer Patients; A Randomized Non-Comparative Phase II Trial
por: Fountzilas, George, et al.
Publicado: (2013)

Protein expression patterns of cell cycle regulators in operable breast cancer
por: Zagouri, Flora, et al.
Publicado: (2017)

Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative
por: Fountzilas, Elena, et al.
Publicado: (2020)

The First Case of Severe Takotsubo Cardiomyopathy Associated with 5-Fluorouracil in a Patient with Abnormalities of Both Dihydropyrimidine Dehydrogenase (DPYD) and Thymidylate Synthase (TYMS) Genes
por: Saif, Muhammad W, et al.
Publicado: (2016)

Dose-dense sequential adjuvant chemotherapy followed, as indicated, by trastuzumab for one year in patients with early breast cancer: first report at 5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase III trial
por: Fountzilas, George, et al.
Publicado: (2014)

XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis
por: Pectasides, Dimitrios, et al.
Publicado: (2012)

In Situ Quantitative Measurement of HER2mRNA Predicts Benefit from Trastuzumab-Containing Chemotherapy in a Cohort of Metastatic Breast Cancer Patients
por: Vassilakopoulou, Maria, et al.
Publicado: (2014)

Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials
por: Kotoula, Vassiliki, et al.
Publicado: (2015)

Tumor Infiltrating Lymphocytes Affect the Outcome of Patients with Operable Triple-Negative Breast Cancer in Combination with Mutated Amino Acid Classes
por: Kotoula, Vassiliki, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_0ul71g54f8aiavr5p42isnag6g